4CMenB vaccine effectiveness: reasons for optimism

Nicole E. Basta, Hannah Christensen

Research output: Contribution to journalComment/debatepeer-review

8 Scopus citations
Original languageEnglish (US)
Pages (from-to)2719-2721
Number of pages3
JournalThe Lancet
Volume388
Issue number10061
DOIs
StatePublished - Dec 3 2016

Bibliographical note

Funding Information:
NEB is funded by the National Institutes of Health Early Independence Award from the Office of the Director ( 1DP5OD009162 ). NEB has collaborated with Ray Borrow and co-authored studies of meningococcal A and B vaccines using data from the USA and Africa. HC is funded by the National Institute for Health Research Health Protection Research Unit (NIHR HPRU) in evaluation of interventions at the University of Bristol in partnership with Public Health England (PHE). HC has collaborated with PHE when developing mathematical and economic models predicting the impact of 4CMenB in the UK and has co-authored papers with PHE colleagues, including Article authors Shamez Ladhani, Helen Campbell, Ray Borrow, and Mary Ramsay, on preventing secondary cases of invasive meningococcal capsular group B (MenB) disease using Bexsero, but she had no involvement in the present Article. HC has received honoraria from Sanofi Pasteur, paid to her employer, and consultancy fees from IMS Health and AstraZeneca. The views expressed are those of the author(s) and not necessarily those of the NIH, NHS, the NIHR, the Department of Health, or Public Health England.

Cite this